文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

利妥昔单抗与硫唑嘌呤用于嗜酸性肉芽肿性多血管炎维持治疗的随机临床试验

Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-10-22

这项双盲双模拟随机优效性试验在法国36家医院纳入98例新诊断或复发性EGPA患者,比较利妥昔单抗与硫唑嘌呤维持治疗对缓解持续时间的影响。

要点

  • 利妥昔单抗维持治疗在28个月内泼尼松≤7.5 mg/d的缓解持续时间未优于硫唑嘌呤。
  • 利妥昔单抗组严重感染发生率更高(46.9% vs 24.5%),主要为严重SARS-CoV-2感染。
  • 两组血管炎复发率分别为14.3%和18.4%,哮喘或鼻窦炎急性加重率分别为32.7%和38.8%。

核心结论

  • 对于新诊断或复发性EGPA患者,利妥昔单抗在改善28个月内泼尼松≤7.5 mg/d条件下总缓解持续时间方面未优于硫唑嘌呤。

研究设计与样本

  • 双盲、双模拟、研究者发起的优效性随机临床试验,2018年3月7日至2022年6月2日从法国36家医院纳入98例EGPA患者。
  • 纳入标准为新诊断EGPA或复发性EGPA,且在标准诱导方案后30至360天内达到血管炎缓解(BVAS为0)。
  • 参与者随机接受口服泼尼松标准化减量,并分别接受利妥昔单抗500 mg每6个月静脉给药共18个月加硫唑嘌呤安慰剂每日口服共24个月(n=49),或利妥昔单抗安慰剂每6个月共18个月加硫唑嘌呤每日口服共24个月(n=49)。

主要发现

  • 至少1次血管炎复发比例分别为7例(14.3%)和9例(18.4%)。
  • 至少1次临床显著哮喘急性加重、鼻窦炎急性加重或两者兼有的比例分别为16例(32.7%)和19例(38.8%)。
  • 利妥昔单抗组严重感染发生率更高(23例[46.9%] vs 12例[24.5%]),主要为严重SARS-CoV-2感染;硫唑嘌呤组1例在疫苗研发前死于SARS-CoV-2感染。

临床怎么用

  • 对于新诊断或复发性EGPA达到缓解后的维持治疗,利妥昔单抗未显示优于硫唑嘌呤的疗效,选择时需权衡严重感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For patients with eosinophilic granulomatosis with polyangiitis (EGPA), guidelines recommend considering maintenance therapy after achieving remission. Data comparing maintenance therapeutic options are limited. OBJECTIVE: To compare the effects of rituximab and azathioprine maintenance therapies on remission duration for patients with EGPA who recently achieved remission of vasculitis after standard therapy, including prednisone tapering or withdrawal. DESIGN, SETTING, AND PARTICIPANTS: From March 7, 2018, to June 2, 2022, this double-blind, double-dummy, investigator-initiated, superiority, randomized clinical trial enrolled 98 participants with EGPA from 36 hospitals in France. Inclusion eligibility required a new EGPA diagnosis or relapsing EGPA within 30 to 360 days of achieving vasculitis remission (Birmingham Vasculitis Activity Score of 0 [range, 0-63, with higher scores indicating more severe disease activity]) after a standard induction regimen. Data were analyzed from April 1, 2025, to September 17, 2025. Additional analyses ended June 22, 2026. INTERVENTIONS: Participants were randomized to receive a predefined standardized tapering of oral prednisone and either 500 mg of intravenous rituximab every 6 months for 18 months and daily oral azathioprine placebo for 24 months (n = 49) or rituximab placebo every 6 months for 18 months and daily oral azathioprine for 24 months (n = 49). MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the duration of total remission during the 28-month study period while taking 7.5 mg/d or less of prednisone. The 14 secondary end points included proportion of participants remaining in remission, rate of vasculitis relapse, and rate of asthma or rhinosinusitis exacerbations. RESULTS: All 98 randomized participants (mean age, 59.0 years [SD, 14.4]; 50 women [51%]) received at least 1 dose of the trial regimen and 92 (94%) completed the trial. The mean time in remission with prednisone at 7.5 mg/d or less was 91.1 weeks (95% CI, 80.9-101.2) vs 96.0 weeks (95% CI, 85.6-106.5) in the rituximab and azathioprine groups, respectively (P = .38). The proportion of participants who remained in remission during the 28-month study period with prednisone at 7.5 mg/d or less was 17 of 49 (34.7%) vs 11 of 49 (22.4%; relative risk, 1.51; 95% CI, 0.83-2.73; P = .18) in the rituximab and azathioprine groups, respectively. The proportion of participants with at least 1 vasculitis relapse was 7 (14.3%) vs 9 (18.4%) in the rituximab vs azathioprine groups, respectively, and for those with at least 1 clinically significant asthma exacerbation, rhinosinusitis exacerbation, or both, it was 16 (32.7%) vs 19 (38.8%). One participant in the azathioprine group died of SARS-CoV-2 infection before vaccine development. Rituximab recipients experienced a higher incidence of severe infections (23 [46.9%] vs 12 [24.5%], respectively), primarily due to severe SARS-CoV-2 infections. CONCLUSIONS AND RELEVANCE: For participants with newly diagnosed or relapsing EGPA, rituximab was not superior to azathioprine for improving the duration of total remission during 28 months while taking prednisone at 7.5 mg/d or less. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03164473.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Puéchal X, Pugnet G, Thoreau B, et al. Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial. JAMA. 2026. PMID: 42911562. doi:10.1001/jama.2026.15278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。